Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Lacosamide
Drug ID BADD_D01238
Description Lacosamide is a functionalized amino acid that has activity in the maximal electroshock seizure test, and is indicated for the adjunctive treatment of partial-onset seizures and diabetic neuropathic pain. Recent studies indicate that Lacosamide only affects those neurons which are depolarized or active for long periods of time, typical of neurons at the focus of an epileptic seizure, as opposed to other antiepileptic drugs such as carbamazepine or lamotrigine which slow the recovery from inactivation and reduce the ability of neurons to fire action potentials.
Indications and Usage Lacosamide is indicated for adjunctive therapy for partial onset seizures in patients with epilepsy over 17 years old. Injection is indicated for short term use when oral therapy is not feasible.
Marketing Status approved
ATC Code N03AX18
DrugBank ID DB06218
KEGG ID D07299
MeSH ID D000078334
PubChem ID 219078
TTD Drug ID D05OFX
NDC Product Code 73289-0063; 73289-0064; 14445-012; 66651-914; 16714-549; 27808-246; 0131-5410; 47335-918; 50228-193; 51407-721; 51991-348; 51991-349; 60687-698; 65162-923; 65162-926; 68083-480; 68462-680; 69539-026; 72865-235; 36998-1810; 0904-7244; 65977-0075; 14445-132; 31722-627; 31722-814; 31722-815; 0131-2479; 42291-862; 47335-980; 53746-925; 66689-108; 69543-455; 70710-1886; 0904-7246; 0904-7247; 65372-1186; 0131-2478; 47335-922; 53746-926; 60687-676; 65862-749; 66689-109; 67877-736; 68462-678; 68462-681; 62332-173; 65862-747; 12828-0087; 14445-021; 42765-060; 65862-720; 68225-057; 14445-129; 14445-130; 31722-813; 60505-0405; 62332-171; 65219-204; 65862-748; 69367-350; 72603-140; 13612-0021; 0904-7245; 50370-0024; 66039-882; 27808-244; 31722-812; 0131-1810; 46708-171; 47335-943; 50228-192; 62332-172; 62332-174; 69367-348; 70771-1682; 36998-2478; 16714-552; 27808-245; 0131-2480; 42291-860; 42934-303; 46708-172; 46708-173; 51407-722; 51991-351; 60687-687; 67877-733; 67877-735; 69367-351; 69539-025; 70954-488; 36998-0119; 36998-2480; 52038-005; 53747-069; 62331-062; 16714-548; 25021-791; 31722-203; 0121-1012; 0121-2024; 46708-174; 51991-350; 65162-924; 65162-925; 66689-107; 67877-734; 69539-027; 72205-220; 72266-242; 16436-0101; 17180-2746; 36998-2477; 36998-2479; 16714-550; 53746-924; 65862-750; 66689-110; 69539-028; 73289-0065; 17205-107; 0131-2477; 42291-861; 42291-863; 50228-194; 51407-723; 51407-724; 53746-923; 68462-679; 69367-349; 70710-1359; 14445-131; 14445-406; 27808-243; 50228-195
UNII 563KS2PQY5
Synonyms Lacosamide | Vimpat | N-benzyl-2-acetamido-3-methoxypropionamide | N benzyl 2 acetamido 3 methoxypropionamide | N-benzyl-AcMeOPrNH2 | N benzyl AcMeOPrNH2
Chemical Information
Molecular Formula C13H18N2O3
CAS Registry Number 175481-36-4
SMILES CC(=O)NC(COC)C(=O)NCC1=CC=CC=C1
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Hypernatraemia14.05.04.0010.001463%
Hypersensitivity10.01.03.003--
Hypersomnia17.15.01.001; 19.02.05.0010.005704%
Hypoaesthesia23.03.03.081; 17.02.06.023--Not Available
Hypokinesia17.01.02.0090.001463%Not Available
Hyponatraemia14.05.04.0020.011555%
Hypothermia12.05.03.001; 08.05.01.0030.004680%
Hypotonia17.05.02.002; 15.05.04.0080.001463%Not Available
Ileus07.13.01.0010.001463%
Immune system disorder10.02.01.001--Not Available
Increased appetite14.03.01.003; 08.01.09.0270.003218%Not Available
Injection site pain12.07.03.011; 08.02.03.010--Not Available
Insomnia19.02.01.002; 17.15.03.002--
Intentional self-injury19.12.01.002; 12.01.08.0360.009361%Not Available
Irritability19.04.02.013; 08.01.03.0110.026181%
Lethargy19.04.04.004; 17.02.04.003; 08.01.01.0080.009653%
Leukopenia01.02.02.0010.005119%Not Available
Liver function test abnormal13.03.04.030--Not Available
Loss of consciousness17.02.04.0040.011994%Not Available
Marasmus14.03.02.0130.001463%Not Available
Memory impairment19.20.01.003; 17.03.02.0030.011555%
Mood altered19.04.02.007--Not Available
Mood swings19.04.03.001--Not Available
Muscle spasms15.05.03.004--
Muscle spasticity17.05.03.007; 15.05.04.0110.001463%
Muscle twitching15.05.03.0050.003949%Not Available
Mydriasis17.02.11.003; 06.05.03.0040.003949%Not Available
Myelodysplastic syndrome01.10.04.001; 16.01.04.0010.002194%
Myoclonus17.02.05.0080.009361%Not Available
Nausea07.01.07.001--
The 5th Page    First    Pre   5 6 7 8 9    Next   Last    Total 10 Pages